Now showing items 1-6 of 6
Oro-mucosal midazolam maleate: Use and effectiveness in adults with epilepsy in the UK.
BACKGROUND: Oro-mucosal midazolam maleate (OMM) with suitable training to family and carers is being increasingly recognized as the treatment of choice to mitigate the development of status epilepticus in non-hospital ...
Eslicarbazepine acetate response in intellectual disability population versus general population.
BACKGROUND: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic ...
Valproate prescribing practices for women with intellectual disability across Europe.
BACKGROUND: Valproate (VPA) is a known teratogen associated with greater risk of major congenital malformations and other neurodevelopmental sequelae than all other licensed antiepileptic medicines. To reduce the potential ...
European perspective of perampanel response in people with Intellectual Disability.
BACKGROUND: Epilepsy prevalence is over 20% for those with ID. It is difficult to diagnose and treat and more likely to be treatment resistant. The evidence informing prescribing is sparse, particularly for new drugs such ...
The evidence for switching dibenzazepines in people with epilepsy.
The dibenzazepines particularly carbamazepine are associated with known adverse effects (AEs) and drug to drug interactions. Eslicarbazepine acetate (ESL) is structurally distinct from other members of the dibenzazepine ...
Valproate risk form-Surveying 215 clinicians involving 4775 encounters.
OBJECTIVES: Annual completion of a Valproate Risk Acknowledgement Form (RAF) is mandated in the United Kingdom due to neurodevelopmental risks of in utero valproate exposure. The number of women of childbearing potential ...